Two Sigma Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-7,200
| Closed | -$734K | – | 2640 |
|
|
2023
Q2 | $734K | Sell |
7,200
-28,000
| -80% | -$2.85M | ﹤0.01% | 1663 |
|
|
2023
Q1 | $3.2M | Sell |
35,200
-15,000
| -30% | -$1.36M | 0.01% | 1020 |
|
|
2022
Q4 | $1.91M | Buy |
50,200
+25,200
| +101% | +$957K | 0.01% | 1271 |
|
|
2022
Q3 | $628K | Buy |
+25,000
| New | +$628K | ﹤0.01% | 1746 |
|
|
2020
Q4 | – | Sell |
-51,989
| Closed | -$5.07M | – | 2647 |
|
|
2020
Q3 | $5.07M | Sell |
51,989
-9,100
| -15% | -$887K | 0.01% | 762 |
|
|
2020
Q2 | $9.53M | Buy |
61,089
+54,800
| +871% | +$8.55M | 0.03% | 572 |
|
|
2020
Q1 | $908K | Buy |
+6,289
| New | +$908K | ﹤0.01% | 1540 |
|
|
2019
Q2 | – | Sell |
-3,156
| Closed | -$270K | – | 2481 |
|
|
2019
Q1 | $270K | Buy |
+3,156
| New | +$270K | ﹤0.01% | 2020 |
|